Breast Cancer: Assessing Response to Neoadjuvant Chemotherapy by Using US-guided Near-Infrared Tomography

Published Online:https://doi.org/10.1148/radiol.12112415

Our initial findings indicate that pretreatment breast tumor hemoglobin content is a strong predictor of response to neoadjuvant chemotherapy and that the percentage of total hemoglobin changes normalized to the pretreatment level can be used to further differentiate responders from nonresponders in early treatment cycles.

Purpose

To assess initial breast tumor hemoglobin (Hb) content before the initiation of neoadjuvant chemotherapy, monitor the Hb changes at the end of each treatment cycle, and correlate these findings with tumor pathologic response.

Materials and Methods

The HIPAA-compliant study protocol was approved by the institutional review boards of both institutions. Written informed consent was obtained from all patients. Patients who were eligible for neoadjuvant chemotherapy were recruited between December 2007 and May 2011, and their tumor Hb content was assessed by using a near-infrared imager coupled with an ultrasonography (US) system. Thirty-two women (mean age, 48 years; range, 32–82 years) were imaged before treatment, at the end of every treatment cycle, and before definitive surgery. The patients were graded in terms of their final pathologic response on the basis of the Miller-Payne system as nonresponders and partial responders (grades 1–3) and near-complete and complete responders (grades 4 and 5). Tumor vascularity was assessed from total Hb (tHb), oxygenated Hb (oxyHb), and deoxygenated Hb (deoxyHb) concentrations. Tumor vascularity changes during treatment were assessed from percentage tHb normalized to the pretreatment level. A two-sample two-sided t test was used to calculate the P value and to evaluate statistical significance between groups. Bonferroni-Holm correction was applied to obtain the corrected P value for multiple comparisons.

Results

There were 20 Miller-Payne grade 1–3 tumors and 14 grade 4 or 5 tumors. Mean maximum pretreatment tHb, oxyHb, and deoxyHb levels were significantly higher in grade 4 and 5 tumors than in grade 1–3 tumors (P = .005, P = .008, and P = .017, respectively). The mean percentage tHb changes were significantly higher in grade 4 or 5 tumors than in grade 1–3 tumors at the end of treatment cycles 1–3 (P = .009 and corrected P = .009, P = .002 and corrected P = .004, and P < .001 and corrected P < .001, respectively).

Discussion

These findings indicate that initial tumor Hb content is a strong predictor of final pathologic response. Additionally, the tHb changes during early treatment cycles can further predict final pathologic response.

© RSNA, 2012

Supplemental material: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.12112415/-/DC1

References

  • 1 Fisher B, Brown A, Mamounas E, et al.. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15(7):2483–2493.
  • 2 Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;(30):96–102.
  • 3 Rastogi P, Anderson SJ, Bear HD, et al.. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26(5):778–785.
  • 4 Denley H, Pinder SE, Elston CW, Lee AH, Ellis IO. Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol 2001;54(1):20–24.
  • 5 Rakha EA, El-Sayed ME, Green AR, et al.. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007;25(30):4772–4778.
  • 6 Chuthapisith S, Eremin JM, Eremin O. Predicting response to neoadjuvant chemotherapy in breast cancer: molecular imaging, systemic biomarkers and the cancer metabolome (review). Oncol Rep 2008;20(4):699–703.
  • 7 Nicholson RI, Johnston SR. Endocrine therapy: current benefits and limitations. Breast Cancer Res Treat 2005;93(Suppl 1):S3–S10.
  • 8 Tokunaga E, Oki E, Nishida K, et al.. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol 2006;11(3):199–208.
  • 9 Chagpar AB, Middleton LP, Sahin AA, et al.. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 2006;243(2):257–264.
  • 10 Loo CE, Straver ME, Rodenhuis S, et al.. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 2011;29(6):660–666.
  • 11 Miller BT, Abbott AM, Tuttle TM. The influence of preoperative MRI on breast cancer treatment. Ann Surg Oncol 2012;19(2):536–540.
  • 12 Groheux D, Giacchetti S, Espié M, Rubello D, Moretti JL, Hindié E. Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging 2011;38(3):419–425.
  • 13 Tromberg BJ, Cerussi A, Shah N, et al.. Imaging in breast cancer: diffuse optics in breast cancer—detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy. Breast Cancer Res 2005;7(6):279–285.
  • 14 Chance B, Nioka S, Zhang J, et al.. Breast cancer detection based on incremental biochemical and physiological properties of breast cancers: a six-year, two-site study. Acad Radiol 2005;12(8):925–933.
  • 15 Spinelli L, Torricelli A, Pifferi A, Taroni P, Danesini G, Cubeddu R. Characterization of female breast lesions from multi-wavelength time-resolved optical mammography. Phys Med Biol 2005;50(11):2489–2502.
  • 16 Grosenick D, Moesta KT, Möller M, et al.. Time-domain scanning optical mammography. I. Recording and assessment of mammograms of 154 patients. Phys Med Biol 2005;50(11):2429–2449.
  • 17 Poplack SP, Tosteson TD, Wells WA, et al.. Electromagnetic breast imaging: results of a pilot study in women with abnormal mammograms. Radiology 2007;243(2):350–359.
  • 18 Zhu Q, Cronin EB, Currier AA, et al.. Benign versus malignant breast masses: optical differentiation with US-guided optical imaging reconstruction. Radiology 2005;237(1):57–66.
  • 19 Liang X, Zhang Q, Li C, Grobmyer SR, Fajardo LL, Jiang H. Phase-contrast diffuse optical tomography: pilot results in the breast. Acad Radiol 2008;15(7):859–866.
  • 20 Choe R, Konecky SD, Corlu A, et al.. Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography. J Biomed Opt 2009;14(2):024020.
  • 21 Zhu Q, Hegde PU, Ricci A, et al.. Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis. Radiology 2010;256(2):367–378.
  • 22 Fang Q, Selb J, Carp SA, et al.. Combined optical and X-ray tomosynthesis breast imaging. Radiology 2011;258(1):89–97.
  • 23 Cerussi A, Hsiang D, Shah N, et al.. Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy. Proc Natl Acad Sci U S A 2007;104(10):4014–4019.
  • 24 Zhou C, Choe R, Shah N, et al.. Diffuse optical monitoring of blood flow and oxygenation in human breast cancer during early stages of neoadjuvant chemotherapy. J Biomed Opt 2007;12(5):051903.
  • 25 Zhu Q, Tannenbaum S, Hegde P, Kane M, Xu C, Kurtzman SH. Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization. Neoplasia 2008;10(10):1028–1040.
  • 26 Jiang S, Pogue BW, Carpenter CM, et al.. Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes. Radiology 2009;252(2):551–560.
  • 27 Soliman H, Gunasekara A, Rycroft M, et al.. Functional imaging using diffuse optical spectroscopy of neoadjuvant chemotherapy response in women with locally advanced breast cancer. Clin Cancer Res 2010;16(9):2605–2614.
  • 28 Roblyer D, Ueda S, Cerussi A, et al.. Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment. Proc Natl Acad Sci U S A 2011;108(35):14626–14631.
  • 29 Zhu Q, Huang M, Chen N, et al.. Ultrasound-guided optical tomographic imaging of malignant and benign breast lesions: initial clinical results of 19 cases. Neoplasia 2003;5(5):379–388.
  • 30 Zhu Q, Chen N, Kurtzman SH. Imaging tumor angiogenesis by use of combined near-infrared diffusive light and ultrasound. Opt Lett 2003;28(5):337–339.
  • 31 Ogston KN, Miller ID, Payne S, et al.. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003;12(5):320–327.
  • 32 Zhu Q, Xu C, Guo P, et al.. Optimal probing of optical contrast of breast lesions of different size located at different depths by US localization. Technol Cancer Res Treat 2006;5(4):365–380.
  • 33 Xu Y, Zhu Q. Imaging heterogeneous absorption distribution of advanced breast cancer by optical tomography. J Biomed Opt 2010;15(6):066007.
  • 34 Biswal NC, Xu Y, Zhu Q. Imaging tumor oxyhemoglobin and deoxyhemoglobin concentrations with ultrasound-guided diffuse optical tomography. Technol Cancer Res Treat 2011;10(5):417–429.
  • 35 Kuo WH, Chen CN, Hsieh FJ, et al.. Vascularity change and tumor response to neoadjuvant chemotherapy for advanced breast cancer. Ultrasound Med Biol 2008;34(6):857–866.

Article History

Received November 18, 2011; revision requested January 16, 2012; revision received April 24; accepted May 7; final version accepted August 23.
Published online: Feb 2013
Published in print: Feb 2013